Oudshoorn M, van Leeuwen A, van Rood J J
Europdonor Foundation, University Hospital Leiden, The Netherlands.
Beitr Infusionsther Transfusionsmed. 1994;32:250-5.
Bone marrow transplantation has become the treatment of choice for many hematological malignancies. Approximately 30% of the patients lack an HLA-identical sibling donor, for them alternative donors have to be found. The chances of finding an unrelated donor can be estimated by consulting the Bone Marrow Donors Worldwide file and grouping the patients according to whether they have frequent or rare haplotypes. If the HLA-ABDR split antigens are taken into account, for less than 25% of the patients identical donors can be identified. In order to select the best matched donor for a patient, sensitive HLA typing techniques should be employed including DNA typing techniques, but for optimal selection of a suitable donor one should not only study genetics but also determine the immunological repertoire recognizing the histocompatibility differences between donor and recipient. Several promising cellular techniques such as the HTLp and CTLp test have recently become available and should also be used to select the best donor.
骨髓移植已成为许多血液系统恶性肿瘤的首选治疗方法。约30%的患者缺乏HLA配型相同的同胞供者,对于他们而言,必须寻找其他供者。通过查阅全球骨髓供者档案并根据患者单倍型频率高低进行分组,可以估算找到非血缘供者的几率。如果考虑HLA-ABDR分型抗原,能为不到25%的患者找到配型相同的供者。为患者选择最佳配型供者时,应采用敏感的HLA分型技术,包括DNA分型技术,但为了最佳选择合适的供者,不仅要研究遗传学,还应确定识别供者与受者之间组织相容性差异的免疫库。最近已有几种有前景的细胞技术,如HTLp和CTLp检测,也应用于选择最佳供者。